Merova is also called rituximab, the treatment does not exist the recurrence rate of the statement, only after long-term use of the drug will be ineffective.
Rituximab is a kind of targeted therapy drugs, can act precisely on the tumor, stabilize the patient’s condition but not achieve the effect of cure, so there is no claim of relapse again, only after taking the drug for about one and a half years there will be drug resistance, can not achieve the therapeutic effect, so that the condition of the new progress.
Rituximab is mainly used for CD20-positive B-cell malignant lymphoma, untreated CD20-positive diffuse large B-cell lymphoma patients, can effectively prolong the survival cycle of the patient, during the use of the drug may be dyspnea, rhinitis, vomiting and other adverse reactions, the patient should not self-medication.